Online citations, reference lists, and bibliographies.
← Back to Search

FDG PET/CT In The Management Of Primary Pleural Tumors And Pleural Metastases.

Matthew J. Kruse, S. Sherry, Vasavi Paidpally, G. Mercier, R. Subramaniam
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE. FDG PET/CT is emerging as an important modality in the evaluation of pleural tumors. PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma. This modality has distinct advantages in characterizing other primary pleural tumors and pleural metastases. CONCLUSION. FDG PET/CT is a useful imaging modality in the management of patients with primary pleural tumors and pleural metastases.
This paper references
10.1097/01.rlu.0000257269.99345.1b
Contribution of F-18 FDG PET-CT in the Detection of Systemic Spread of Primary Central Nervous System Lymphoma
D. Karantanis (2007)
10.1016/J.EJCTS.2007.05.027
Diagnosis, treatment and long-term outcome of solitary fibrous tumours of the pleura.
M. Kohler (2007)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a clinical practice guideline
P. Ellis (2012)
10.1111/j.1754-9485.2011.02274.x
Establishing locoregional control of malignant pleural mesothelioma using high‐dose radiotherapy and 18F‐FDG PET/CT scan correlation
M. Feigen (2011)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
10.1055/s-2008-1039314
The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
A. Orki (2009)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1158/1078-0432.CCR-08-2258
High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer
Young Joo Lee (2009)
10.1007/s00408-003-1002-5
[18F]-FDG PET and Localized Fibrous Mesothelioma
J. Cortés (2003)
10.1007/s00259-012-2280-z
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours
C. Wiele (2012)
10.1136/thx.24.1.69
Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis 1
G. Jones (1969)
10.1007/s12149-008-0225-1
The effect of 18F-FDG-PET/CT respiratory gating on detected metabolic activity in lung lesions
A. Lupi (2009)
10.1016/j.crad.2009.03.010
CT appearances of pleural tumours.
H. Salahudeen (2009)
10.1002/JSO.2930570111
Pleural dissemination in non‐small cell lung cancer: Results of radiological evaluation and surgical treatment
E. Akaogi (1994)
10.1016/S0003-4975(01)03374-4
Solitary fibrous tumors of the pleura.
M. D. de Perrot (2002)
10.1378/CHEST.111.6.1710
Revisions in the International System for Staging Lung Cancer.
C. Mountain (1997)
10.7785/tcrt.2012.500245
Prognostic Value of 18F-FDG Standard Uptake Value by Integrated PET/CT in the Staging of Malignant Pleural Mesothelioma
G. Genestreti (2012)
10.1097/00000478-198908000-00003
Localized Benign and Malignant Fibrous Tumors of the Pleura: A Clinicopathologic Review of 223 Cases
D. England (1989)
10.1177/107327480601300403
Solitary fibrous tumor of the pleura.
L. Robinson (2006)
10.1002/1097-0142(19810601)47:11<2678::AID-CNCR2820471126>3.0.CO;2-9
Solitary fibrous tumors of the pleura: Eight new cases and review of 360 cases in the literature
M. Briselli (1981)
10.1002/1097-0142(197910)44:4<1465::AID-CNCR2820440441>3.0.CO;2-Y
Localized primary tumors of the pleura. An analysis of 40 cases
W. Dalton (1979)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
10.1148/radiol.10091479
Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake.
J. Davison (2010)
10.1097/JTO.0B013E31805FE2A5
Hibernoma: 18F FDG PET/CT imaging.
R. Subramaniam (2007)
10.1016/J.LUNGCAN.2005.03.009
Prognostic factors in mesothelioma.
J. Steele (2002)
10.1016/J.CRAD.2006.06.008
Benign localized fibrous tumour of the pleura: CT features with histopathological correlations.
S. Chong (2006)
10.1016/J.CCM.2006.02.001
Imaging of pleural disease.
N. R. Qureshi (2006)
10.1016/S0720-048X(00)00168-6
Malignant pleural disease.
B. Feragalli (2003)
10.2214/AJR.10.4884
Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
Heather M Imsande (2011)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
F. Bénard (1999)
10.2214/AJR.09.2516
Respiratory gating enhances imaging of pulmonary nodules and measurement of tracer uptake in FDG PET/CT.
M. Werner (2009)
10.1378/CHEST.122.6.1918
Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
N. Gupta (2002)
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
V. Gerbaudo (2002)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1097/RLU.0b013e3181bece11
F-18 FDG PET/CT Characterization of Talc Pleurodesis-Induced Pleural Changes Over Time: A Retrospective Study
N. Nguyen (2009)
10.2214/AJR.10.6331
Value of PET/CT in the management of liver metastases, part 1.
Ari Sacks (2011)
10.1097/JTO.0b013e3182653d64
Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series
F. Lococo (2012)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1378/CHEST.125.6.2356
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
10.1136/THX.52.2.187
Evaluation of pleural diseases with FDG-PET imaging: preliminary report.
T. Bury (1997)
10.2967/jnumed.111.099531
18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging
Elizabeth H Dibble (2012)
10.1186/1748-717X-4-35
Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma
B. Pehlivan (2009)
10.1378/CHEST.125.2.489
Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
B. Duysinx (2004)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1055/s-0029-1241029
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
J. Pilling (2010)
10.1016/S0169-5002(98)00083-X
The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.
A. Knuuttila (1998)
10.2214/AJR.11.8182
PET/CT of cancer patients: part 1, pancreatic neoplasms.
Elizabeth H Dibble (2012)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1056/NEJMOA022136
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
D. Lardinois (2003)
10.1097/01.rct.0000185383.50636.d1
Integrated PET/CT and the Dry Pleural Dissemination of Peripheral Adenocarcinoma of the Lung: Diagnostic Implications
S. S. Shim (2006)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1111/j.1754-9485.2009.02058.x
18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma *
R. Subramaniam (2009)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1007/s11604-010-0484-3
Malignant solitary fibrous tumor of the pleura: computed tomography-pathological correlation and comparison with computed tomography of benign solitary fibrous tumor of the pleura
S. W. Song (2010)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1016/j.athoracsur.2009.07.026
Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution.
G. Cardillo (2009)
10.2214/AJR.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
10.1186/1749-8090-2-48
Pleural myxoid liposarcoma: features of 2 cases and associated literature review
P. Goldsmith (2007)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1016/0720-048X(94)90278-X
Localized pleural fibroma: radiological features.
P. Versluis (1994)
10.2214/AJR.11.7076
Spectrum of malignant pleural and pericardial disease on FDG PET/CT.
W. Makis (2012)
PET for the evaluation of pleural thickening observed on CT.
H. Kramer (2004)
10.1097/00005382-199807000-00009
Helical Computed Tomography Diagnosis of Pleural Dissemination in Lung Cancer: Comparison of Thick‐Section and Thin‐Section Helical Computed Tomography
K. Mori (1998)
10.1016/j.ejrad.2010.11.006
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
N. Schaefer (2012)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/j.athoracsur.2012.04.028
Solitary fibrous tumor of the pleura: outcomes of 157 complete resections in a single center.
B. Lahon (2012)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1148/RG.233025165
From the archives of the AFIP: Localized fibrous tumor of the pleura.
M. Rosado-de-Christenson (2003)
10.1007/s11547-008-0345-7
Fibrous tumour of the pleura (SFTP): a proteiform disease. Clinical, histological and atypical radiological patterns selected among our cases
L. Cardinale (2008)
10.1007/s00259-010-1704-x
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival
V. Gerbaudo (2010)
10.1097/JTO.0b013e318031d05c
Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study
M. Lucchi (2007)
10.3892/or.2011.1520
Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Y. Abe (2012)
10.5761/ATCS.CR.10.01589
Giant solitary fibrous tumour of pleura -an uncommon intrathoracic entity- a case report and review of the literature.
Rohan G Thakkar (2011)
10.1093/JJCO/HYL073
Surgery for dedifferentiated liposarcoma, presenting two radiologically and pathologically distinctive patterns.
M. Hoshi (2006)
10.1148/RADIOLOGY.191.2.8153309
Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.
E. Patz (1994)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1148/RADIOL.2313030785
Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
G. Schaffler (2004)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.2214/AJR.169.2.9242783
Lipoma and liposarcoma: evaluation using CT and MR imaging.
P. Munk (1997)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1043/0003-9985(2000)124<0699:LOTPC>2.0.CO;2
Liposarcoma of the pleural cavity: clinical and pathologic features of 4 cases with a review of the literature.
Okby Nt (2000)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1007/s12149-012-0575-6
Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with 18F-FDG PET/CT
Min-Young Jung (2012)
10.2214/AJR.175.1.1750245
FDG PET of pleural effusions in patients with non-small cell lung cancer.
J. Erasmus (2000)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.3413/NUKMED-0091
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
S. Krüger (2007)
10.1007/s11307-009-0212-5
Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
A. Mavi (2009)
10.1007/s11307-010-0426-6
Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment
S. Basu (2010)
10.1055/s-0030-1269827
Imaging of the pleura.
John Ayres (2010)
10.1164/rccm.201103-0554CR
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
D. Sterman (2011)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)



This paper is referenced by
10.17265/2328-2150/2016.11.006
Value of FDG PET/CT in the Management of Mesothelioma
Mohamad Faizul Abu Hanifa (2016)
10.1007/978-3-030-39457-8_21
PET in Lung Cancer and Mediastinal Malignancies
F. Gaertner (2020)
10.1038/srep28757
Stereotactic Comparison Study of 18F-Alfatide and 18F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model
Yu-Chun Wei (2016)
10.4274/balkanmedj.2017.0350
Solitary Fibrous Tumors of Chest: Another Look with the Oncologic Perspective
M. Saynak (2017)
10.1097/MCP.0000000000000267
Phenotyping malignant pleural effusions
M. M. S. Lui (2016)
10.1016/j.ccm.2017.11.004
Malignant Pleural Effusion: From Diagnostics to Therapeutics.
R. Asciak (2018)
Role of PET / CT in Diagnosis and Staging of Malignant Mesothelioma
D. I. Mohamed (2017)
10.2214/AJR.13.12420
FDG PET/CT in the management of nasopharyngeal carcinoma.
Aravind Mohandas (2014)
10.1097/MNM.0000000000000211
Fluorine-18-deoxyglucose positron emission tomography/computed tomography with Ki67 and GLUT-1 immunohistochemistry for evaluation of the radiosensitization effect of oleanolic acid on C6 rat gliomas
Y. Zhang (2015)
Solitary Fibrous Tumor of the Pleura: multimodal imaging findings with pathologic correlation
Erika Arenas Rivera (2017)
10.1155/2017/4972701
Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug
M. Chen (2017)
10.2214/AJR.11.7076
Spectrum of malignant pleural and pericardial disease on FDG PET/CT.
W. Makis (2012)
10.1177/1753465816628800
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
10.1967/s002449910904
18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
A. Niccoli Asabella (2018)
10.1016/j.rcl.2015.12.006
Solitary Fibrous Tumors: 2016 Imaging Update.
A. Keraliya (2016)
10.1007/s00259-014-2960-y
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
Original Article Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma
Yukako Ichimiya (2015)
10.1007/978-3-319-89893-3_3
PET Hybrid Imaging of the Thorax
D. Neriman (2018)
10.2214/AJR.13.12256
FDG PET/CT in the management of colorectal and anal cancers.
A. Agarwal (2014)
10.2214/AJR.11.8182
PET/CT of cancer patients: part 1, pancreatic neoplasms.
Elizabeth H Dibble (2012)
Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.
Y. Ichimiya (2015)
10.1021/acsami.7b09331
Construction and Evaluation of a Targeted Hyaluronic Acid Nanoparticle/Photosensitizer Complex for Cancer Photodynamic Therapy.
Shi Gao (2017)
Semantic Scholar Logo Some data provided by SemanticScholar